Description of Blood Analysis: 

Circulating anticoagulants are abnormal inhibitors, often antibodies, produced by the immune system that interfere with the blood’s ability to clot. These substances can target specific clotting proteins or phospholipids, leading to unpredictable changes in coagulation. The presence of these inhibitors can cause a paradoxical state where the body is prone to either excessive bleeding or dangerous clotting. Identifying these components acts as a biochemical marker for complex immune-related disruptions within the hematological system.

What does the analysis represent?

• Purpose: Detection of endogenous inhibitors that interfere with clotting factor activity.
• Primary Application: Investigating unexplained prolonged clotting times and screening for autoimmune-related clotting risks.
• Method: Specialized mixing studies and factor-specific assays of a venous blood sample.

Recommendations for the Test (General)

• Timing: Morning collection is recommended for optimal laboratory stability.
• Fasting: A fasting pause of 8–12 hours is required to prevent interference from dietary fats.
• Rest: Sit calmly for 20 minutes before the blood draw to stabilize immune markers.
• Specific Rules: The test should ideally be performed before the initiation of any pharmaceutical anticoagulant therapy.

What can affect the results?

• Factors altering levels: Current treatment with blood-thinning medications, recent acute infections, and improper handling of the blood sample during processing.

When to take the test?

• Recommendations: Ordered when basic clotting tests remain abnormal despite being mixed with normal plasma or in cases of recurrent pregnancy loss.
• Preparation: Best performed when the patient is not in the acute phase of an inflammatory illness.

How to interpret the results? 

Data interpretation is the exclusive responsibility of a physician. Finding a circulating anticoagulant is a significant indicator that requires a detailed review of the patient’s immune health. The physician must distinguish between temporary inhibitors caused by illness and chronic inhibitors associated with autoimmune conditions. Only an expert can determine the long-term clinical risks and necessary management strategies.

Possible further investigations

• Lupus Anticoagulant Panel: To confirm the presence of phospholipid-dependent antibodies.
• Anti-Nuclear Antibody (ANA) Test: To check for broader autoimmune activity.
• Hematologist Consultation: A follow-up to develop a specialized plan for managing clotting risks.

When does the next step make sense? 

If circulating anticoagulants are detected, results are reviewed by a doctor to decide on the necessity of long-term immune monitoring or preventative treatment. Decisions on follow-up care are always made individually based on the confirmed inhibitor type.

👉 If necessary, you can discuss the analysis results with a specialist such as an hematologist (Doctors – TAMC).